Adjudin delays cellular senescence through Sirt3‑mediated attenuation of ROS production

Area of Science:

• Cellular Biology
• Aging Research
• Pharmacology

Background:

• Aging is characterized by cellular and functional decline, linked to pathologies like cancer and neurodegeneration.
• Accumulation of reactive oxygen species (ROS) is a key driver of aging and associated diseases.
• Cellular senescence, a state of irreversible growth arrest, is a hallmark of aging and can be induced by agents like hydroxyurea.

Purpose of the Study:

• To investigate the anti-senescence effects of adjudin, a multi-functional small molecule compound.
• To elucidate the molecular mechanisms underlying adjudin's potential anti-aging properties.
• To determine the role of Sirtuin 3 (Sirt3) in mediating adjudin's anti-senescence effects.

Main Methods:

• Hydroxyurea was used to induce cellular senescence in mouse embryo fibroblasts (MEFs).
• Adjudin's effect on senescence markers (senescence-associated β-galactosidase, p16, p21) and ROS production was assessed.
• Sirt3 expression levels and its downstream targets (FOXO3a, MnSOD) were analyzed.
• Experiments were conducted using both wild-type and Sirt3-knockout MEFs to confirm Sirt3's role.

Main Results:

• Adjudin significantly delayed hydroxyurea-induced senescence in MEFs.
• Adjudin reduced the percentage of senescence-associated β-galactosidase-positive cells and decreased p16 and p21 expression.
• Adjudin elevated Sirt3 expression, which in turn attenuated ROS production by regulating FOXO3a and manganese superoxide dismutase (MnSOD).
• The anti-senescence effect of adjudin was dependent on Sirt3, as demonstrated in Sirt3-knockout MEFs.

Conclusions:

• Adjudin exhibits significant anti-aging properties by delaying cellular senescence.
• The mechanism involves the upregulation of Sirt3, leading to reduced ROS production.
• Adjudin represents a potential therapeutic agent for treating aging-associated diseases.